Diabetes and Colorectal Cancer Risk and Survival According to Tumor Immunity Status
Article 2025 en
Authors
DW
Durgesh Wankhede
NH
Niels Halama
MK
Matthias Kloor
Abstract
1 min read
T2D disproportionately affects CRC risk and survival in tumors with low immune infiltration, suggesting a continuum of T2D's impact from tumorigenesis to prognosis, through systemic and tumor-specific immune modulation. These findings highlight the need for precision prevention strategies integrating metabolic and immune-based interventions to mitigate CRC burden in patients with T2D.
Tafirenyika Gwenzi, Durgesh Wankhede, Tanwei Yuan, Megha Bhardwaj, Petra Schrotz‐King, Sophie C. Anker, Ben Schöttker, Michael Hoffmeister, Hermann Brenner
Héctor G. Pálmer, Lorena Ramírez, Javier Ros, Oriol Arqués, Jordi Martínez‐Quintanilla, Débora Cabot, Alex Mur-Espinosa, Irene Chicote, Isabel Puig, Gilles Flamen, Ángel de la Torre, Ania Alay, Luna Martín, Raquel Flores, Ariadna García, José Jiménez, Verónica Dávalos, Lara Nonell, Xavier Solé, David P. Kodack, Patrizia Barzaghi-Rinaudo, Lisa Kattenhorn, Slavica Dimitrieva, Paolo Nucíforo, Manel Esteller, Françesc Canals, Ana Vivancos, Diana Graus Porta, Josep Tabernero, Elena Élez
Marta L. Pinto, Elisabete Rios, Cecília Durães, Ricardo Ribeiro, José Carlos Machado, Alberto Mantovani, Mário A. Barbosa, Fátima Carneiro, María José Oliveira
Discussion(0)
No comments yet. Be the first to comment.